Evaxion Biotech A/S (NASDAQ:EVAX) Trading Down 0.3% – Here’s What Happened

Evaxion Biotech A/S (NASDAQ:EVAX) dropped 0.3% during trading on Wednesday . The company traded as low as $1.43 and last traded at $1.47. Approximately 23,639 shares traded hands during trading, a decline of 96% from the average daily volume of 602,037 shares. The stock had previously closed at $1.47.

Wall Street Analyst Weigh In

Several research firms have recently weighed in on EVAX. HC Wainwright reaffirmed a “buy” rating and set a $14.00 price objective on shares of Evaxion Biotech A/S in a research report on Wednesday, April 2nd. Lake Street Capital decreased their price target on shares of Evaxion Biotech A/S from $35.00 to $6.00 and set a “buy” rating for the company in a research note on Tuesday, February 4th.

Evaxion Biotech A/S Stock Down 0.3 %

The firm’s 50-day simple moving average is $1.62 and its 200 day simple moving average is $4.61. The company has a debt-to-equity ratio of 7.99, a quick ratio of 2.80 and a current ratio of 1.00. The stock has a market capitalization of $2.06 million, a P/E ratio of -1.01 and a beta of -0.24.

Evaxion Biotech A/S (NASDAQ:EVAX) last released its earnings results on Tuesday, April 1st. The company reported ($0.07) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.26) by $0.19. The company had revenue of $0.12 million during the quarter, compared to analyst estimates of $1.66 million. As a group, research analysts expect that Evaxion Biotech A/S will post -0.15 EPS for the current year.

Institutional Investors Weigh In On Evaxion Biotech A/S

A hedge fund recently raised its stake in Evaxion Biotech A/S stock. Invst LLC boosted its position in shares of Evaxion Biotech A/S (NASDAQ:EVAX) by 16.7% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 50,400 shares of the company’s stock after acquiring an additional 7,200 shares during the quarter. Invst LLC owned 4.31% of Evaxion Biotech A/S worth $43,000 at the end of the most recent reporting period. 11.04% of the stock is currently owned by institutional investors.

Evaxion Biotech A/S Company Profile

Evaxion Biotech A/S, a clinical-stage biotech company, engages in developing artificial intelligence-powered immunotherapies. The company develops EVX-01, which is in phase 2 global multi-center clinical trial for the treatment of metastatic melanoma; EVX-02, a DNA-based vaccine that is in Phase 1/2a trial designed to induce a therapeutic immune response in the adjuvant setting in patients with resected melanoma; and EVX-03, DNA-based cancer vaccine for the treatment of various cancers.